Production of a novel humanised anti Dendritic Cell Therapeutic Antibody for Graft Versus Host Disease

用于移植物抗宿主病的新型人源化抗树突状细胞治疗抗体的生产

• 批准号: nhmrc : 434523
• 负责人: Dr David Munster
• 金额: $ 13.5万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-01-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/production-novel-humanised-host-disease/88173
• 关键词: Production; novel; humanised; anti; Dendritic

A transplant of bone marrow or other source of blood stem cells from a donor is often used to treat leukaemia patients whose disease has failed to respond to chemotherapy. The Mater Medical Research Institute has developed a world first dendritic cell depleting therapeutic antibody which may open a new strategy for the control of acute graft versus host disease, which is a very common and often fatal complication of bone marrow transplantation. The new antibody treatment is also likely to be useful for the prevention of rejection in solid organ transplantation. If successful, it will selectively control graft versus host disease, without compromising the essential anti-viral immunity and desired anti-leukemia activity of the graft.

来自捐赠者的骨髓或其他来源的造血干细胞移植通常用于治疗对化疗无效的白血病患者。马特医学研究所开发了世界上第一个消除树突状细胞的治疗性抗体，该抗体可能为控制急性移植物抗宿主病开辟新策略，急性移植物抗宿主病是骨髓移植的一种非常常见且往往致命的并发症。新的抗体治疗也可能有助于预防实体器官移植中的排斥反应。如果成功，它将选择性地控制移植物抗宿主疾病，而不损害移植物的基本抗病毒免疫力和所需的抗白血病活性。